Category Archives: Pharmacogenomics

Wei Gordon, Tetrad, delivered her first-prize winning research at Grad Slam 2022, titled, Uncovering the Sweet Secrets of Fruit-Eating Mammals, at the Grad Divisions annual student research competition held for the first time in three years, in Byers Hall, at the Mission Bay campus. Image by Susan Merrell

The prevalence of sugary foods in our diets has contributed to the rise of diabetes now the eighth leading cause of death in the United States. Human bodies arent equipped to handle so much sugar, but mammals adapted for sugary diets, like fruit-eating bats and primates have the ability to lower their blood sugar faster.

Wei Gordon, a PhD student in UC San Franciscos Tetrad Program, is studying the genetic secrets of these sugar-eating animals and her talk on this work won first prize in this years UCSF Grad Slam.

She was among nine finalists in the sixth annual UCSF Grad Slam, held March 31 after a two-year hiatus due to the pandemic competing to inform and entertain with three-minute talks based on their own research. Their talks reflected the broad range of science research conducted at UCSF, from designing culturally competent care for COVID-19, to fighting bacteria with phages, to understanding the misfolded proteins that lead to dementia.

The live event was held in front of a limited but enthusiastic audience in Byers Auditorium and live-streamed online. Nicquet Blake, PhD, dean of the Graduate Division and vice provost of Student Academic Affairs, provided opening remarks and awarded prizes, and Elizabeth Silva, PhD, associate dean for graduate programs, emceed the program. A panel of judges selected first-, second-, and third-prize winners. Both in-person and online audiences were able to vote for the Peoples Choice winner.

Gordon, who is a PhD student in the lab of Nadav Ahituv, PhD, took home the $4,000 first-place prize with her talk, Uncovering the Sweet Secrets of Fruit-Eating Mammals, which described her research into the thousands of DNA mutations present only in fruit-eating mammals. In particular, she is focusing on so-called gene regulatory regions, which serve as the conductors directing the work of genes, or the instruments. She impressed the judges with her confident delivery, which she credited to her love of theater.

I know that Im a very expressive person, so I tried to make sure to have some fun in the presentation, she said. The process of preparing for Grad Slam showed her the difficulty of breaking down scientific terms and also the power of metaphors to communicate complex ideas, she said.

Gordon will go on to represent UCSF at the UC system-wide Grad Slam event on May 6.

Coming in second place, with a prize of $2,000, was Rachel Nakagawa, a PhD student in the Biomedical Sciences Program. In her talk, Deconstructing Tumor Cell Interactions, Nakagawa outlined the challenge of treating solid tumor cancers, which consist of diverse communities of cells that can work together to thwart therapies. Parsing these interactions is like trying to eavesdrop at a crowded party, she said, so she is deconstructing them into simpler parts that could one day be targeted by drugs.

Luca Abascal Miguel, a PhD student in the Global Health Sciences Program, won the third-place spot with her talk, No le Pidas Peras al Olmo/Dont Ask the Elm Tree for Pears, the first UCSF Grad Slam talk given in Spanish. Abascal Miguel described the language, cultural and socioeconomic barriers that have contributed to COVID-19s disproportionate impact on the Latinx community in California. Studying these barriers allowed her to help develop effective targeted interventions for these communities.

The Peoples Choice award chosen by the live and remote viewing audiences went to Gokul Ramadoss, a PhD student in the Biomedical Sciences Program. In his talk, entitled Get Your Genes Tailored, he discussed his research into tools that could potentially treat the genetic typos that lead to devastating brain diseases like ALS.

These were the other finalists in this years live competition:

Neha Prasad (Chemistry and Chemical Biology), Our Friend, the Phage

Jack Stevenson (Chemistry and Chemical Biology), Learning the Tricks of the Most Valuable Protein: How Your Cells Decide to Divide

Megan Chong (Tetrad), Nobodys Perfect, But Dividing Cells Can Work It

Colin Germer (Pharmaceutical Sciences and Pharmacogenomics), Bursting Every Stress Bubble the Eye Can See

Kelly Montgomery (Chemistry and Chemical Biology), Paper Cranes and Paper Balls, Unfolding the Causes of Dementia

The finalists were selected by a panel of screening judges from entries submitted by video. from entries submitted by video.

The judges of the live event were Erin Allday, health reporter for the San Francisco Chronicle; Won HA, MA, UCSFs vice chancellor for communications; Catherine Lucey, MD, executive vice dean, vice dean for education and professor of medicine at the UCSF School of Medicine; Leticia Mrquez-Magaa, PhD, professor of biology and director of the Health Equity Research Laboratory at San Francisco State University; and Don Woodson, MEd, director of UCSFs Center for Science Education and Outreach.

All the finalists did an incredible job weaving in the creative use of metaphor and simile into their presentations on topics of such complexity, said Ha. He added that the judges aligned easily in their deliberations and decided on the winners unanimously.

Graduate Dean Nicquet Blake, PhD, who joined UCSF in December, remarked Grad Slam was the most fun Ive had since I arrived in San Francisco. I was told it was an awesome event, and it did not disappoint! It was gratifying to see our students creative approaches to making really important and timely research accessible for a general audience. In the process, they honed their science communication and advocacy skills that will serve them well no matter where their career path takes them. I congratulate all the finalists on a job well done, and I cant wait to tune in and cheer Wei on at the systemwide Grad Slam on May 6!

Read more:
Talk on the Secrets of Fruit-Eating Mammals Wins 2022 UCSF Grad Slam - University of California, San Francisco

Newswise Two out of three women diagnosed with depression or anxiety say they have reached or are approaching their breaking point regarding their mental health, according to the GeneSightMental Health Monitor, a new nationwide survey from Myriad Genetics, Inc. (NASDAQ: MYGN).

This breaking point can include a negative impact or a significant strain on anything from social life to caring for loved ones at home to professional obligations. Four out of 10 womenwithout a diagnosis ofdepression or anxiety say they have reached or are reaching this point.

When feeling overwhelmed, nearly three in four (72%) of women say they "just need to take a break, with 31% believing I need to try harder. Only 13% said they thought I should see a doctor when feeling overwhelmed.

Women often feel pressure to hold it all together and not admit when they are struggling, says Dr. Betty Jo BJ Fancher, a family medicine and psychiatric physician assistant with a doctorate of medical science and a masters in psychopharmacology. Yet, if you are sobbing on the floor of your shower, throwing things in anger or repeatedly screaming into a pillow, these are signals that you have crossed a line and should see a healthcare provider about your mental health.

Delaying mental health treatment is common among the women surveyed. In fact, more than half (51%) of women diagnosed with anxiety and/or depression waited at least one year before seeking treatment or never sought treatment at all.

The GeneSight Mental Health Monitor found that women are waiting more than a year longer than they should to get the mental health treatment they need, noted Rachael Earls, PhD, a medical science liaison with Myriad Genetics, makers of the GeneSight test. It is critical to receive treatment for mental health because we know that mental health conditions are highly comorbid with other physical diseases, such as cancer, stroke, heart disease. Why live with a mental health condition that can impact every aspect of your life until you reach a breaking point?

According to the survey, the top reasons women diagnosed with depression or anxiety delayed treatment are:

Will my concerns be validated or ignored?

The reluctance by some women to seek treatment may be rooted in how their mental health concerns have been received by family and friends.

Six in 10 of the women surveyed with depression or anxiety diagnosis say they have been ignored or dismissed by family, friends, and/or partners about their mental health concerns. Less than half of women (44%) say they talk to friends or family to relieve stress and anxiety.

I have friends who wont talk to their parents about how they are struggling because they are afraid of their parents reaction, says Ansley, daughter of Dr. Fancher and a senior at the University of Georgia, who has been diagnosed with depression, anxiety and ADHD. Therapy has helped me, so I know the benefits of talking to someone about your mental health. When friends or classmates say they are suffering with depression or anxiety, I encourage them to reach out to someone and get the help they need.

Despite available treatment options, fewer than two in 10 women believe they will ever be free from anxiety or depression symptoms.

Getting personalized treatment

Six in 10 women diagnosed with depression or anxiety agree that taking a prescription medication was the most helpful step in treating their anxiety or depression symptoms, more than any other action or treatment option offered in the survey, including therapy.

Only about 30% of women who have been prescribed psychiatric medication are aware of genetic testing that may help their physicians with prescribing decisions and only 8% of these respondents have had genetic testing. Yet, 67% of diagnosed women whose doctor didnotuse genetic testingsaid they wish their doctor had told them about and/or offered a genetic test that could provide information about how their genes may affect medication outcomes.

Dr. Fancher orders the GeneSight test to get personalized genetic information about her patients that helps her understand how they may metabolize or respond to certain medications commonly used to treat depression, anxiety, ADHD and other mental health conditions.

Having the genetic information from the GeneSight test at my fingertips to help inform my medication selection makes me a better provider, said Dr. Fancher.

Ansleys mental health provider also uses the GeneSight test. She made adjustments based on my results, and I am happy to say that everything is working really well, said Ansley.

For more information on how genetic testing can help inform clinicians on treatment of depression, anxiety, ADHD, and other psychiatric conditions, please visitGeneSight.com. To download graphics, a multimedia video and other information regarding the survey, please visitGeneSight.com/Mental-Health-Monitor.

About the GeneSightMental Health MonitorThe GeneSight Mental Health Monitor is a nationwide survey of U.S. adults conducted online by ACUPOLL Precision Research, Inc. from Feb. 25 March 11, 2022, among a statistically representative sample (n=1000) of adults age 18+. The survey included a representative sample of women diagnosed with depression and anxiety. The margin of error in survey results for the total base population at a 95% confidence interval is +/- 3%.

About the GeneSight TestThe GeneSight Psychotropic test from Myriad Genetics is the category-leading pharmacogenomic test for 64 medications commonly prescribed for depression, anxiety, ADHD, and other psychiatric conditions. The GeneSight test can help inform clinicians about how a patients genes may impact how they metabolize and/or respond to certain psychiatric medications. It has been given to more than 1.5 million patients by tens of thousands of clinicians to provide genetic information that is unique to each patient. The GeneSight test supplements other information considered by a clinician as part of a comprehensive medical assessment. Learn more atGeneSight.com.

About Myriad GeneticsMyriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs.Fast Companynamed Myriad among the Worlds Most Innovative Companies for 2022. For more information, visitwww.myriad.com.

Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, Colaris AP, MyRisk, Myriad MyRisk, MyRisk Hereditary Cancer, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Precise, FirstGene, Health.Illuminated., RiskScore, Prolaris, GeneSight, and EndoPredict are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries.

View original post here:
2 Out of 3 Women with Depression or Anxiety Say TheyVe Reached Their Breaking Point, Yet More Than Half Wait a Year Before Seeking Treatment -...

DUBLIN, Jan. 26, 2022 /PRNewswire/ -- The "Microarray Market 2021-2027" report has been added to ResearchAndMarkets.com's offering.

The global microarray market is anticipated to grow at a substantial CAGR of 7.8% during the forecast period. The global microarray market is driven by the rising prevalence of cancer as well as increased funding for genomic research.

Additionally, the rapidly evolving information and software technology, as well as emerging bioinformatics, are also some of the factors driving the microarray market, making it cost-effective, dependable, and long-lasting. However, a lack of skilled professionals and the growing penetration of next-generation DNA sequencing techniques are considered to address significant challenges to market growth.

The global microarray market witnessed positive growth during the COVID-19 pandemic as huge efforts to manufacture vaccines, develop new drugs, deployment of test kits was fueling the growth of the biotechnology sector. The COVID-19 pandemic has also increased the use of microarrays techniques in pharmaceutical research.

The global microarray market is segmented based on type, and application; Based on type, the market is segmented into DNA microarrays, protein microarray, peptide microarray, tissue microarray, and others (cellular microarray). Further based on application, the market is segregated into diagnosis and prognosis, Pharmacogenomics and theragnostic, and drug discovery, and others. The DNA Microarray segment is expected to have a significant share of the global microarray market attributing to the increasing applications of the DNA microarray approach in various sectors, such as gene expression, proteomics, disease monitoring, and drug discovery.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific is the fastest-growing market for microarray. Factors such as increased emphasis on personalized medicine, an increase in cancer diagnostic rates, and technological advancements are largely responsible for fueling the growth of this market. The Asia-Pacific region is also expected to grow significantly as a result of increased government funding in the healthcare sector. As per IBEF, the healthcare sector in India received $679 million in investment in 2018. These government initiatives are expected to increase demand for microarrays used in research, therefore, fueling the demand for microarrays in the Asia-Pacific market.

Market Segmentation

The Report Covers

Key Topics Covered:

1. Report Summary

2. Market Overview and Insights2.1. Scope of the Report2.2. Analyst Insight & Current Market Trends2.2.1. Key Findings2.2.2. Recommendations2.2.3. Conclusion2.3. Regulations

3. Competitive Landscape3.1. Key Company Analysis3.1.1. Overview3.1.2. Financial Analysis3.1.3. SWOT Analysis3.2. Key Strategy Analysis3.3. Impact of COVID-19 on key players

4. Market Determinants4.1. Motivators4.2. Restraints4.3. Opportunities

5. Market Segmentation5.1. Global Microarray Market by Type5.1.1. DNA Microarrays5.1.2. Protein Microarray5.1.3. Peptide Microarray5.1.4. Tissue Microarray5.1.5. Others (Cellular Microarray)5.2. Global Microarray Market by Application5.2.1. Diagnosis and Prognosis5.2.2. Pharmacogenomics and Theragnostic5.2.3. Drug Discovery5.2.4. Others

6. Regional Analysis

7. Company Profiles7.1. Abcam PLC7.2. Agilent Technologies, Inc.7.3. Applied Microarrays, Inc.7.4. Arrayit Corp.7.5. Aurora Biomed Inc.7.6. Bio-Rad Laboratories, Inc.7.7. F. Hoffmann-La Roche Ltd.7.8. Merck KGaA7.9. Meso Scale Diagnostics, LLC.7.10. Origene Technologies, Inc.7.11. Pantomics, Inc.7.12. Partek, Inc.7.13. PerkinElmer, Inc.7.14. Takara Bio, Inc.7.15. Thermo Fisher Scientific, Inc.7.16. US Biomax, Inc.7.17. Illumina, Inc.7.18. Indevr, Inc.7.19. Luminex Corp.7.20. RayBiotech, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/cjcawv

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Read the original:
Outlook on the Microarray Global Market to 2027 - by Type, Application and Region - PRNewswire

Global Molecular Diagnostic Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis. It also provides market information in terms of development and its capacities.

MR Accuracy Reports crafted the report, titled Global Molecular Diagnostic Market 2021 is a methodical research study based on the Molecular Diagnostic Market, analyzing the competitive framework of the industry in the world. Using efficient analytical tools such as SWOT analysis and Porters five forces analysis, the report provides a comprehensive assessment of the Molecular Diagnostic Market. Our big research team were able to captured all-important chapters in the final report as they have been striving towards it.

Download Free PDF Sample Reportwith Complete TOC and Figures & Graphs (withcovid 19Impact Analysis):https://www.mraccuracyreports.com/report-sample/499394

Molecular diagnostics is growing rapidly. Molecular diagnostic tests detect specific sequences in DNA or RNA that may or may not be associated with disease, including single nucleotide polymorphism (SNP), deletions, rearrangements, insertions and others. Clinical applications can be found in at least six general areas: infectious diseases; oncology; pharmacogenomics; genetic disease screening; human leukocyte antigen typing; and coagulation.

The report forecast global Molecular Diagnostic market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2021E-2026F due to coronavirus situation.

The report offers detailed coverage of Molecular Diagnostic industry and main market trends with impact of coronavirus. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Molecular Diagnostic by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

First, this report covers the present status and the future prospects of the global Molecular Diagnostic market for 2016-2025.

And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].

At the same time, we classify Molecular Diagnostic according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.

Finally, the report provides detailed profile and data information analysis of leading Molecular Diagnostic company.

Key Content of Chapters as follows (Including and can be customized) :

Part 1:

Market Overview, Development, and Segment by Type, Application & Region

Part 2:

Company information, Sales, Cost, Margin etc.

Part 3:

Global Market by company, Type, Application & Geography

Part 4:

Asia-Pacific Market by Type, Application & Geography

Part 5:

Europe Market by Type, Application & Geography

Part 6:

North America Market by Type, Application & Geography

Part 7:

South America Market by Type, Application & Geography

Part 8:

Middle East & Africa Market by Type, Application & Geography

Part 9:

Market Features

Part 10:

Investment Opportunity

Part 11:

Conclusion

Market Segment as follows:

By Region

Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]

Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]

North America[United States, Canada, Mexico]

Middle East & Africa[GCC, North Africa, South Africa]

South America[Brazil, Argentina, Columbia, Chile, Peru]

Key Companies

Roche

Abbott

Gen-Probe

Danaher

Thermo Fisher

Siemens

Qiagen

BD

Biomerieux

GE

Market by Type

PCR instrument

ISH instrument

Gene chip matching Equipment

Market by Application

Prenatal

Infectious disease

Cancer

Others

GetExclusive Discount on this report:https://www.mraccuracyreports.com/check-discount/499394

Key questions answered in the report include:

If you have any special requirements, please let us know and we will offer you the report as you want

You can buy the complete report@ https://www.mraccuracyreports.com/checkout/499394

About Us:

MR Accuracy Reports well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future. Our research reports arm our clients with macro-level insights across various key global regions that equip them with a broader perspective to align their strategies to capitalize on lucrative growth opportunities in the market.

Contact Us:MR Accuracy Reports,USA: +1 804 500 1224UK: +44 741841 3666 ASIA: +91 747888728100Email: sales@mraccuracyreports.com Website: https://www.mraccuracyreports.com

Originally posted here:
Molecular Diagnostic Market 2021 Opportunity And Competitive Landscape Forecast to 2028 The Oxford Spokesman - The Oxford Spokesman

One of the next big shifts in patient care will be precision medicine will be"an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment and lifestyle for each person," as the Precision Medicine Initiative describes it.

For physicians and researchersthis means predicting more accurately which treatment and prevention strategies for a particular disease will work in particular groups of people.

This is completely different from the traditional one-size-fits-all approach, in which treatment and prevention strategies are developed for the average person, with less consideration for the differences between individuals.

What does this mean for healthcare and health IT? A lot of new challenges. Because precision medicine and genomics generate massive volumes of varied and granular data, new approaches to data storage and exchangeand new designs for electronic health records,for example, may be required. Physician education and patient communication are two other areas that will demand attention

Some advanced healthcare provider organizations, such as large academic medical centers,are already well-advanced in their precision medicine efforts. But most providers are still early in the journey, if they're attempting it at all. But many are preparing today for what many think will be the next step in the evolution of healthcare.

This story, focused on precision medicine and other emerging technologies, is the sixth and final installment in Healthcare IT News' feature series, "Health IT Investment: The Next Five Years."

The series offers interviews with primarily CIOs to learn from them the path forward through the priorities they set with their investments in six categories: AI and machine learning; interoperability; telehealth, connected health and remote patient monitoring; cybersecurity; electronic health records and population health; and precision medicine and other emerging technologies. Click here to access all the features.

The six health IT leaders discussing their plans for the next five years in this sixth and final installment in the series include:

Precision medicine has been an organizational priority for UPMC for more than a decade, and it has an ambitious vision of using it to provide better, more personalized care and improved outcomes for patients.

"Through these efforts, we aim to create new insights into the drivers of health and disease to allow the discovery of innovative therapies and models of care, while also lowering the cost of care by avoiding diagnostic delays and therapeutic dead ends," said Kleinz of UPMC.

"As one of the largest integrated healthcare delivery and insurance organizations, UPMC has the scale, capabilities and ambition to lead the discovery, assessment and clinical deployment of impactful precision medicine approaches," he continued.

Dr. Matthias J. Kleinz, UPMC Enterprises

"Our efforts are led by the Institute for Precision Medicine, which was established in 2014 in collaboration with our academic research partner, the University of Pittsburgh."

The mission for the institute is to accelerate translational and clinical research in precision medicine and to deliver the most advanced prediction and treatment of disease, tailored to an individual's unique circumstances, history and condition.

"In this context, we have and will continue to make significant investments in established molecular and genomic tests [and]emerging proteomic, metabolomic, and microbiome assay technology, and drive the discovery of highly personalized precision therapeutic approaches, including cell, gene and regenerative medicines," Kleinz explained.

Investment in deployment and development of novel technologies is an important pillar inunlocking the value of precision medicine.

UPMC has made a number of significant initial investments in the following areas, Kleinz noted, and is continuing to evaluate new opportunities:

"UPMC's leadership strongly supports this vision and already has invested heavily in the implementation of precision medicine," he said. "The appropriate use of precision medicine approaches benefits first and foremost our patients, but also supports our providers as they deliver care across the UPMC system.

"The tangible benefits are streamlined clinical workflows, improved patient outcomes, and the potential to optimize resource allocation and reduce the long-term cost of care," he continued.

"We are dedicated to continuing the aggressive rollout of precision medicine, both through internal efforts and increasingly through creative partnerships with industry, such as our partnership with proteomics company Somalogic."

Sanford Health believes precision medicine will be the future of healthcare, so it continues to make significant investments in this space.

"Leveraging machine learning and high computational power to analyze data sets containing genetic, clinical and socioeconomic data will not only help design the best personalized treatment for our patients, but also will help identify those patients or patient populations that would benefit most from early screening and interventions to prevent disease," said Hocks of Sanford Health.

Matt Hocks, Sanford Health

"Precision medicine will allow us to concentrate our efforts on prevention and early screening, diagnosis, and care that will help keep our patients healthy and thriving for generations to come," he added. "Cancer care and chronic disease management are burdensome to patients, communities and health systems. Concentrating resources to prevent these conditions will benefit us all."

Mobile health is an area of health IT that has been emerging in recent years. The same with remote patient monitoring, which has especially gained ground during the COVID-19 pandemic. Virginia Hospital Center is on top of both.

"Virginia Hospital Center does not view itself as cutting-edge when it comes to technology," Mistretta said. "It considers itself more of a fast, early adopter of new technology it believes may provide an advantage to its patients.

"We are extremely patient-focused, so many of our investments moving forward are going to be in that realm," he continued. "We will be investing in hospital-at-home and remote patient monitoring features in depth, along with other patient engagement functions to empower our population and maintain low-touch care to minimize costs."

Mike Mistretta, Virginia Hospital Center

Mobility is in demand by patients, so connecting through web and app technologies will be a high priority, he added.

"We need to make care convenient for patients and provide care on their terms," he observed. "In our Northern Virginia/D.C. market, we hear about this frequently due to traffic and distance considerations."

Thus the development of pilot programs like the organization's OB Connect, where patients followed for maternity care are issued home equipment, post resultsand are able to skip the office if everything is within expected limits. Mistretta believes this kind of technology will permeate the market.

"These types of technologies will be required to sustain significant growth for health systems," he said. "Combined with the effective use of data to produce appropriate metrics, we should be able to pinpoint more specific markets and what treatments produce more effective outcomes.

"It also is the only way we will be able to meet the significant demands that will be placed on the care system with the shortage of nursing and primary care resources predicted to hit in the coming years," he added. "We simply will not be able to continue to experience the same results and levels of treatment enjoyed today as the population grows and ages without providing increased care outside the walls of our traditional organizational structures."

Leadership buy-in on a different approach will take some time, but with successes along the way (and supporting data to reinforce), healthcare organizations will be able to achieve what will be needed, he said.

Providence pledged to invest $50 million over five years in health equity. Here is a recap of how it invested in year one.

Elsewhere, Moore is concerned with the internet of things.

"The internet of things is it it's smart devices," he said. "We may give our patients smart devices that sit in our care delivery environments, and have the telemetry information, and go into our big data model. Because that's how we're really going to make these machine learning and artificial intelligence models shine.

B.J. Moore, Providence

"We in healthcare say big data, but until you're working with streams of data, it's not really big data, it's just large data warehouses," he continued. "So getting that remote care delivery data is important, like a temperature four times a day, or real-time streaming of oxygen or heart data."

Moore believes the IoT and the streams of data it can provide are things healthcare executives should be talking about more. "It's all about data volumes: The bigger the volume, the better," he said.

Regenstrief is in the process of developing tools and processes to identify bias in algorithms to improve health equity, said Grannis of Regenstrief Institute.

"As AI becomes more ubiquitous, researchers, clinicians, health systems, industry, government and others must be wary of unintended consequences," he stated. "Our research scientists are working on best practices as well as novel analytical tools to regularly monitor for bias in algorithms, a process Regenstrief and CEO Dr. Peter Emb have coined "algorithmovigilance."

"Over the next five years, Regenstrief will be working with individuals and organizations around the world to implement," he added.

Dr. Shaun Grannis, Regenstrief Institute

Regenstrief also is investing in the broader ecosystem required to sustain advanced AI and machine learning methods. In the same way that clinical decision-makers, including physicians and other care providers, undergo regular training updates and certification due to healthcare's evolving nature and potential for bias, advanced algorithms will need frequent updates and certification to minimize bias and or errors, Grannis said.

Frameworks for overseeing algorithms and analytics are nascent.Developing and evaluating approaches to accurately and efficiently monitor AI and machine learning will become increasingly important in the future of healthcare analytics, he added.

"We also are investing in patient ergonomics the application of human factors,engineering and psychology to the design and evaluation of patient-facing technology to enhance delivery of healthcare," he explained.

"Institute scientists are using user-centered design to create apps that help informal caregivers provide care for their loved ones with Alzheimer's and other chronic conditions. Other apps are exploring the benefits of specific diets and brain-stimulating games."

Babachicos of South Shore Health believes tools that assist patients with care navigation will allow for a more improved and directed patient experience.

"These tools combined with the next-generation call centers also known as patient access centers can be accessed 24/7 by patients looking for care options and direct patients to the right place at the right time for their care needs," she explained. "These patient access centers will use multichannel options such as text, voice and chat while allowing patients to perform many self-service functions, as well.

Cara Babachicos, South Shore Health

"These patient access centers might also be staffed by care navigators for a more human connection when necessary," she concluded. "The same centers could potentially deliver virtual visits/consults, as well as potentially manage patient medications and vitals for subscribed patients in the community."

Twitter:@SiwickiHealthITEmail the writer:bsiwicki@himss.orgHealthcare IT News is a HIMSS Media publication.

Link:
CIOs' 5-year plans for precision medicine and emerging technologies - Healthcare IT News

The World Class Immuno In-Vitro Diagnostics (IVD) Market Research Report makes knowledgeable about the Immuno In-Vitro Diagnostics (IVD) industry and competitive landscape which supports enhanced decision making, better manage marketing of goods and decide market goals for better profitability. Immuno In-Vitro Diagnostics (IVD) market report has been structured after a thorough study of various key market segments like market size, share, growth, demand, latest trends, market threats and key drivers which drives the market. All the statistical data and information involved in this marketing report is characterized properly by using several charts, graphs or tables. The report provides strategically analyzed market research analysis and observant business insights into the most relevant markets of our clients. The winning Immuno In-Vitro Diagnostics (IVD) market research report helps clients recognize new opportunities and most important customers for their business growth and increased revenue.

Immuno In-Vitro Diagnostics (IVD) Market is expected to gain market growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses the market to account to USD 23.97 billion by 2029 and will grow at a CAGR of 4.78% in the above mentioned forecast period.

Download Free Exclusive Sample (350 Pages PDF) Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-immuno-ivd-market

The Immuno In-Vitro Diagnostics (IVD) Market 2022 report brings into focus studies about market definitions, classifications, applications and industry chain structure. Immuno In-Vitro Diagnostics (IVD) Market report is provided for the international markets as well as development trends, competitive landscape analysis, and key regions development status. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report additionally states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. Third by regions, this report focuses on the sales (consumption), production, import and export of Immuno In-Vitro Diagnostics (IVD) in United States, Europe, China, Japan, and Southeast Asia, India.

On the basis of report- titled segments and sub-segment of the market are highlighted below:

ByProduct Type (Reagents, Instruments, Data Management Software, Services) Immunodiagnostics Technique (Enzyme-Linked Immunosorbent Assay, Rapid Tests, Enzyme-Linked ImmunoSpot Assays, Radioimmunoassay, Western Blotting)

By Application (Infectious Diseases, Diabetes, Oncology, Cardiology, Drug Testing/Pharmacogenomics, HIV/AIDS, Autoimmune Diseases, Nephrology, Others)

By End User (Hospital Laboratories, Clinical Laboratories, Point Of Care Testing, Patient Self-Testing, Academic Institutes, Others)

List of Significant Vendors Operating in this market include:

Global Immuno In-Vitro Diagnostics (IVD) Market providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials and instrumentation and downstream demand analysis is additionally dispensed. The Global Immuno In-Vitro Diagnostics (IVD) market development trends and marketing channels are analyzed. Finally, the feasibility of latest investment projects is assessed and overall analysis conclusions offered.

Complete Report is Available (Including Full TOC, List of Tables & Figures, Graphs, and Chart) @ https://www.databridgemarketresearch.com/toc/?dbmr=global-immuno-ivd-market

Global Immuno In-Vitro Diagnostics (IVD) Market Scenario

Immuno in-vitro diagnostics test are generally performed on blood or tissue samples to identify disease or any serious condition. These devices have next generation sequencing tests which can help them to sense genomic variation in person DNA.

The increasing geriatric population and high growth in the prevalence of chronic and infectious diseases is amongst the important factors intensifying the growth and demand of immuno in-vitro diagnostics (IVD) market. In addition, the high adoption of fully automated and POC instruments in emerging regions and increasing geriatric population are also contributing to the growth in the global market over the forecast period of 2021 to 2028. Also the rising awareness regarding disease diagnosis and increasing R&D investments by industry players to launch new IVD products are also enhancing the growth of the market. Furthermore, the higher disposable income and expansion of automated in vitro diagnostic systems for laboratories and hospitals to give resourceful, precise and error-free diagnosis are also one of the significant factors fueling the growth of the immuno in-vitro diagnostics (IVD) market. Increases vulnerability to acquiring various diseaseswill also make sure high industry growth over the forecast period.

Global Immuno In-Vitro Diagnostics (IVD) Market Scope and Market Size

Immuno in-vitro diagnostics (IVD) market is segmented on the basis of product type, immunodiagnostics technique, application and end user. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of product type, the immuno in-vitro diagnostics (IVD) market is segmented into reagents, instruments, data management software and services. Instruments have further been segmented into semi-automated instruments, fully automated instruments and other instruments.

Immuno in-vitro diagnostics (IVD) market is also segmented on the basis of immunodiagnostics technique into enzyme-linked immunosorbent assay, rapid tests, enzyme-linked immunospot assays, radioimmunoassay and western blotting. Enzyme-linked immunosorbent assay have further been segmented into chemiluminescence immunoassays, fluorescence immunoassays and colorimetric immunoassays.

Based on application, the immuno in-vitro diagnostics (IVD) market is segmented into infectious diseases, diabetes, oncology, cardiology, drug testing/pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology and others.

The end user segment of immuno in-vitro diagnostics (IVD) market is segmented into hospital laboratories, clinical laboratories, point of care testing, patient self-testing, academic institutes and others. Clinical laboratories have further been segmented into large/reference laboratories, medium-sized laboratories and small laboratories.

For stakeholders and business professional for expanding their position in the Immuno In-Vitro Diagnostics (IVD) Market:

Q 1. Which Region offers the most rewarding open doors for the market Ahead of 2022?

Q 2. What are the business threats and Impact of COVID scenario Over the market Growth and Estimation?

Q 3. What are probably the most encouraging, high-development scenarios for Immuno In-Vitro Diagnostics (IVD) movement showcase by applications, types and regions?

Q 4.What segments grab most noteworthy attention in Immuno In-Vitro Diagnostics (IVD) Market in 2022 and beyond?

Q 5. Who are the significant players confronting and developing in Immuno In-Vitro Diagnostics (IVD) Market? Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2015-2029) of the following regions are covered in Chapter 5, 6, 7, 8, 9, 10, 13:o North America (Covered in Chapter 6 and 13)o Europe (Covered in Chapter 7 and 13)o Asia-Pacific (Covered in Chapter 8 and 13)o Middle East and Africa (Covered in Chapter 9 and 13)o South America (Covered in Chapter 10 and 13)

For More Information or Query or Customization Before Buying, Visit @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-immuno-ivd-market

With tables and figures helping analyses worldwide Global Immuno In-Vitro Diagnostics (IVD) market trends, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Table of Content:

Market Overview:The report begins with this section where product overview and highlights of product and application segments of the global Immuno In-Vitro Diagnostics (IVD) Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company:Here, the competition in the Worldwide Immuno In-Vitro Diagnostics (IVD) Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data:As the name suggests, this section gives the sales data of key players of the global Immuno In-Vitro Diagnostics (IVD) Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the global Immuno In-Vitro Diagnostics (IVD) Market.

Market Status and Outlook by Region:In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the global Immuno In-Vitro Diagnostics (IVD) Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User:This section of the research study shows how different end-user/application segments contribute to the global Immuno In-Vitro Diagnostics (IVD) Market.

Market Forecast:Here, the report offers a complete forecast of the global Immuno In-Vitro Diagnostics (IVD) Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion:This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

Browse Complete Report Details@https://www.databridgemarketresearch.com/reports/global-immuno-ivd-market

Customization Service of the Report:

Data Bridge Market Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team (Corporatesales@databridgemarketresearch.com), who will guarantee you to get a report that suits your necessities.

Top Related Report from DBMR:

Anorexiants Market 2022 by Size Estimation, Demand, Trends, Market Dynamics, Competition by Manufacturers-Bausch Health, Virtus, Lannett, Sun Pharmaceutical

Diabetic Macular Edema (DME) Market Size, Share, Trends 2022, Demand, Growth, Development| F. Hoffmann-La Roche Ltd, Novartis AG, GlaxoSmithKline plc

Antacids Market Size, Share, Growth, Industry Overview, New Opportunities & SWOT Analysis by 2029| Top Key Players: Perrigo Company plc, Johnson & Johnson Services, Salix Pharmaceuticals

Cancer Monoclonal Antibodies Market 2022 Growth, Segments, Industry by Size, Share, Demand, Trends and Top Companies Overview to 2029| Abbvie, Pfizer, Amgen, Novartis AG

Gastritis Market 2022 Global Industry Size, Demand, Growth Analysis, Share, Revenue and Forecast 2029

Acetaminophen (Paracetamol) Market Share, Size- 2022 Industry Trends, Progress Insight, Developing Technologies, Competitive, Regional, And Global Industry Forecast to 2029

Laxative Market 2022 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis, And Key Country Forecast to 2029

Electrostatic Disinfectant Sprayer Industry 2022 Global Market Size, Growth, Share, Emerging Demand, Current Trends, Company Profiles, Competitive Landscape and Forecasts till 2029

Care Management Solutions Market 2022 Share, Size, Regional Trend, Future Growth, Leading Players Updates, Industry Demand, Current and Future Plans by Forecast to 2029

Artificial Intelligence (AI) In Drug Discovery Market 2022 Industry Demand, Share, Statistics, Global Trend, Top Key Players Update and Forecast to 2029

Hospital Electronic Medical Records (EMR) Systems Market 2022 Global Industry Size, Share, Forecasts Analysis, Company Profiles, Competitive Landscape and Key Regions 2029

Why Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delves into the markets across Asia, North America, South America, and Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate

Contact Us:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

E-Mail:Corporatsesales@databridgemarketresearch.com

See the original post:
Immuno In-Vitro Diagnostics (IVD) Market 2022 Growth, Segments, Industry by Size, Share, Demand, Trends and Top Companies Overview to 2029 | F....